All News
Filter News
Found 809,065 articles
-
NexImmune Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial Officer
1/9/2020
NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation nanotechnology platform, announced that industry veterans Han Myint, MD, and John Trainer, MBA, have been appointed as the Company’s Chief Medical Officer and Chief Financial Officer, respectively.
-
Royal Biologics Launches MAGNUS, a DMSO-free Viable Cellular Bone AllograftExpands its portfolio of orthobiologic solutions for fusion in orthopedics, ideal for bone graft-based procedures
1/9/2020
Royal Biologics, an orthobiologics company specializing in the research and advancement of regenerative cellular therapy and novel orthobiologic solutions, has announced the launch of MAGNUS, a DMSO-free viable cellular bone allograft.
-
AMAG Pharmaceuticals Announces Leadership Transition, Results of Strategic Review to Unlock Shareholder Value and Financial Update
1/9/2020
AMAG Pharmaceuticals, Inc. announced the initiation of a leadership transition, the decision to divest Intrarosa and Vyleesi and financial updates
-
Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth
1/9/2020
Manufacturing veteran Harry Gill joins in newly created role of Senior Vice President, Operations
-
The Delta Companies Promotes DeLibra Wesley to COO
1/9/2020
The firm’s award-winning veteran will oversee daily operations
-
National Health Foundation's Share Table Pilot Program Tapped as Statewide Model
1/9/2020
Faced with the complex issue of food waste and food insecurity in their community, students at Santee Education Complex and Thomas Jefferson High School partnered with National Health Foundation to find a solution.
-
Brady Davis Joins Contextual Genomics’ Executive Team
1/9/2020
Contextual Genomics, a leading cancer genomics company, announced that it has named Brady Davis to its executive team.
-
JOMS study: Jaw surgery improves quality of life in obstructive sleep apnea patients
1/9/2020
Surgery that moves the jaws forward can result in significant improvements in long-term quality of life – including functional outcomes and sleep quality – in patients with obstructive sleep apnea, according to a new study.
-
Parexel Unveils Combined Regulatory & Access Consulting Organization to Help Customers Optimize Delivery of New Therapies to Patients
1/9/2020
Integration of world-class Regulatory and Market Access teams will help companies address Clinical, Regulatory and Market Access strategies in parallel to achieve faster, smarter and patient-led development strategy
-
Adagene to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/9/2020
Adagene, Inc. announced that Peter Luo, Ph.D., Co-founder and Chief Executive Officer, will present an overview of the company at the 38th Annual J.P. Morgan Healthcare Conference.
-
ZAP Surgical Announces US$81 Million Financing Round
1/9/2020
Funds Will Be Used to Accelerate Commercialization of the ZAP-X Robotic Surgical Platform for Non-Invasive Treatment of Brain Tumors Affecting More Than 2 Million Cancer Patients Worldwide
-
Aro Biotherapeutics and Ionis Enter Licensing and Collaboration Agreement Focused on Cell-Specific Delivery of Antisense Oligonucleotides
1/9/2020
Ionis to leverage Aro’s CENTYRIN technology to develop a new class of innovative medicines designed to selectively target antisense oligonucleotides to the source of disease
-
Axcella to Present at J.P. Morgan Healthcare Conference
1/9/2020
Axcella, a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, announced that President and CEO Bill Hinshaw will be presenting at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on January 16, 2020 at 8:30 a.m. PT.
-
New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial
1/9/2020
Data from MEDALIST showed significant clinical benefit of Reblozyl in treating anemia in adults with myelodysplastic syndromes
-
OBI Pharma, Inc. to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/9/2020
OBI Pharma, Inc., a Taiwan biopharma company, announced that Michael Chang, Ph.D. Chairman and CEO, will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2019 at 4:30 p.m. PST/ 7:30 p.m EST, in San Francisco, CA.
-
Regeneron Announces Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare Debilitating Bone Disease
1/9/2020
Approximately 25% decrease in total bone lesions (both new and existing) driven by nearly 90% reduction in formation of new lesions in patients with fibrodysplasia ossificans progressiva (FOP)
-
eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types
1/9/2020
eFFECTOR Therapeutics, Inc. and Pfizer Inc. announced an exclusive worldwide license and collaboration agreement to develop small-molecule inhibitors of eukaryotic initiation factor 4E, a key oncogenic driver located downstream from both the RAS and PI3K signaling pathways.
-
LHC Group to Present at 38th Annual J.P. Morgan Healthcare Conference
1/9/2020
LHC Group, Inc. announced that the Company is presenting at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2020.
-
NeoTherma Oncology Announces FDA IDE Submission to Permit Investigational Treatment of Pancreatic Cancer Patients with Its FDA-Designated Breakthrough Device, the VectRx™ Thermal Oncology System
1/9/2020
NeoTherma Oncology announces they have submitted an Investigational Device Exemption application to the Food and Drug Administration to initiate First-in-Human studies of the VectRx™ System in patients with pancreatic cancer being treated with standard of care chemotherapy under the Early Feasibility Study Guidance.
-
Medtronic Receives CE Mark Approval for the Percept™ PC Neurostimulator DBS System with BrainSense™ Technology
1/9/2020
This Next-Generation DBS Technology Allows Physicians to Review Patient-Specific Brain Signals, Enabling More Personalized, Data-Driven Neurostimulation Treatment for Patients